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ICER. In the case of panitumumab no data were available on progression of disease
in the control group. The solution: progression free survival and survival after
progression of the control group were drawn from the pivotal RCT and adjusted
according to the survival observed in the control group of the outcomes research.
Unadjusted RCT data resulted in an ICER that was approximately 20,000 euro/QALY
higher. CONCLUSIONS: RCT data are often necessary to supplement missing data
that cannot be collected through outcomes research, however the manner in which
RCT data is used can have a profound effect on the resulting cost-effectiveness.
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OBJECTIVES: In cancer, treatments often aim to extend time to progression. The
implications on overall survival are often inconclusive, as trials are too short and
the majority of patients are still alive at the end of the trial. However, for decision
making, it is important to estimate both the treatment effect on Progression Free
Survival as well as the treatment effect on Overall Survival. This poster shows how
the estimation of Overall Survival benefit can be improved by the use of Progression
Free Survival data. METHODS: The developed Network Meta-Analysis model uses
the tested hypothesis that treatments provided until progression in general do not
change the length of the post-progression period. This hypothesis is tested in detail
based on systematic literature reviews concerning 4 different types of cancer. A
test for equal lengths of the post-progression periods is described too. RESULTS: A
network meta-analysis model is described, which can be used to obtain estimates
for OS from PFS data for treatments for which no OS data or insufficient OS data are
available. This informs decision making in situations where otherwise no conclu-
sion can be drawn. The methodology is applied to an indirect comparison of
Chlorambucil, Fludarabine and Fludarabine Cyclophosphamide. Comparable DIC
were obtained to individual fitting of OS and PFS for the situation that OS data were
available. Therefore, the methodology both enables the fitting of OS when OS data
are not available as well as potentially improves OS fitting when data are limited
available. CONCLUSIONS: Based on systematic literature reviews, a method is de-
veloped to use PFS as surrogate outcome for OS. In addition, a test is developed to
justify the assumption of equal post-progression periods among treatments, which
can be used to assess whether the translation of PFS time differences in OS time
differences is appropriate.
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OBJECTIVES: We aimed to assess statistical methods for adjusting survival esti-
mates in the presence of treatment crossover in order to identify which are the
most appropriate in a range of scenarios. Treatment crossover is a common issue in
clinical trials of cancer treatments. Crossover occurs when patients in the control
group switch onto the experimental treatment at some point during follow-up. In
such circumstances an intention to treat (ITT) analysis does not address the deci-
sion problem faced by health technology assessment bodies, and will result in
biased estimates of the overall survival advantage – and therefore the cost-effec-
tiveness – associated with the experimental treatment. METHODS: We conducted
a simulation study to assess the performance of crossover-adjustment methods in
a range of scenarios. We purposefully ran scenarios that did not satisfy the specific
assumptions made by the methods, in order to assess their sensitivities. RESULTS:
Randomisation-based methods (eg Rank Preserving Structural Failure Time Models
(RPSFTM) and Iterative Parameter Estimation (IPE)) were unbiased only when the
treatment effect was not time-dependent. Observational-based methods (eg In-
verse Probability of Censoring Weights (IPCW) and Structural Nested Models
(SNMs) with g-estimation) coped better with time-dependent treatment effects but
are heavily data reliant, are sensitive to model misspecification and often produced
high levels of bias in our simulations. Observational-based methods are particu-
larly sensitive to the proportion of control group patients that crossover whereas
randomisation-based methods are not. CONCLUSIONS: Currently available rando-
misation-based and observational-based methods for addressing treatment cross-
over have important limitations. However, in most circumstances they are likely to
lead to lower bias than an ITT analysis, given the decision problem faced in an
economic evaluation. Analysts should consider the treatment crossover mecha-
nism, the control group crossover proportion, the treatment effect associated with
different patient groups, and data availability when deciding which method to use
to address treatment crossover.
RESEARCH ON METHODS - Cost Methods
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OBJECTIVES: Some European health authorities such as the National Institute of
Clinical Excellence in the UK have published Health Technology Assessment (HTA)
guidelines, which recommend the use of the Quality Adjusted Life Years (QALYs)
outcome measure as the reference case. The ECHOUTCOME project is an interdis-
ciplinary European research platform funded by the seventh Framework Program
of the European Commission which objectives are to assess the validity of the
QALYs for its potential use in cost effectiveness analysis (CEA) in European coun-
tries and proposing new European guidelines for conducting CEA studies.
METHODS: Over a period of 3 months, a total of 1,200 students from Belgium,
France, Italy and the UK answered hypothetical health states in which the health
states and time in a given health states were varied in order to test for: von Neu-
maniann-Morgesten assumptions, mutual independence in utility, and the rele-
vance of the multi-linear multi-attribute utility theory, which are the basis for the
QALY calculation, as currently performed in the HTA literature. RESULTS: The
preliminary findings of the experiment provided strong evidence that utilities ob-
tained by varying the health states and the duration of a given health state fail to
comply with the theoretical basis of the QALY. CONCLUSIONS: The results suggest
that the underlying assumptions of the QALY calculation model are not in line with
behavior from a real life population, implying that the QALY outcome measure
might not be a valid measure for supporting health decision making in Europe. The
findings of this first European experimental survey testing the validity of the QA-
LYoutcome measure should be considered by European member states before rec-
ommending such approach in HTA guidelines.
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OBJECTIVES: The World Health Organisation (WHO) Guide to Identify the Eco-
nomic Consequences of Disease and Injury described the financial burden of poor
health for government both in terms of increased transfer costs and lost tax reve-
nue due to reduced productivity. To evaluate the broader consequences of rotavi-
rus we developed a quantitative “government perspective” framework to evaluate
immunisation costs in Ghana. METHODS: Methods from generational accounting,
human capital economics and epidemiologic modelling were combined to esti-
mate the benefits of rotavirus vaccination in terms of measures used in financial
analyses such as the Net Present Value (NPV) and Return on Investment (ROI). Data
from the published literature and national statistical sources were collected. Single
and multiple cohort models were developed simulating survival, direct medical
costs and average lifetime fiscal transfers between the government and individuals
with and without the vaccination until the age of 65 years. Direct and indirect tax
rates were linked to differences in lifetime age-specific earnings to quantify the tax
revenue associated with vaccinated and unvaccinated individuals. RESULTS: From
a “government perspective” the results showed that every dollar invested on vac-
cination against rotavirus, may yield a discounted gross tax ROI equal to $2.9 and a
net tax ROI of $0.55. The vaccinated and unvaccinated cohorts resulted in total
lifetime discounted net tax of -$167 million -$174 million, for the vaccinated and
unvaccinated cohorts, respectively. The results suggested a net fiscal benefit of
approximately $7million and $54 million for the single and multiple birth cohorts,
respectively. CONCLUSIONS: Vaccinating against rotavirus may result in consid-
erable fiscal benefits. Investments in vaccinations may influence future govern-
ment tax revenue and thus contribute to the sustainability of tax-financed health
systems, public finances and economic growth. Estimating the broader economic
impact of vaccines using the “government perspective” framework may inform
cross-sectoral governmental resource allocation decisions.
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OBJECTIVES: There is a great heterogeneity across health economic studies with
regard to claim of cost inputs making comparison of costs complicated. Objective
was to analyze data availability, corresponding limitations and improvement
approaches. METHODS: We evaluate the availability of cost data capture for Ger-
many, Spain, France and USA. In Germany data from the Hospital Remuneration,
the German Hospital Society (DKG) and the two outpatient tariffs were considered
as well as Medicare, Medicaid and HCUP databases for USA, Database of Ministry of
Health and regional/national official bulletins for Spain and lastly data from SNI-
RAM (Social Security information system) and PMSI (Programme de médicalisation
des systèmes d’information) for France. RESULTS: DRG database in Germany and
USA reflect the reimbursement level more than real cost per indication. Fragmen-
tation of these costs is not possible. The DKG normal tariff (DKG-NT) is listing
detailed procedures and services used for example for reimbursement between
two hospitals. The Spanish inpatient cost data are difficult to collect due to the
prospective hospital global budget; health authorities publish annually DRG and
outpatient procedure tariffs as reference of their own resources cost. In France
SNIRAM data is limited to Social Security own needs. In contrast publicly available
PMSI data allows inpatient information tracking related to specific medical proce-
dure use.Regarding outpatient setting, the physician fee schedule is based on the
Uniform Evaluation Scale (EBM) and the medical fee schedule (GOA¨) for SHI and
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private sector respectively in Germany and on the Medicare physician fee schedule
in USA. In USA is very difficult to analyze physician’s cost of production. In Spain
regional outpatient tariffs are used as resource components without inclusion of
health staff cost.CONCLUSIONS:Cost data availability is limited and varies widely.
An improvement approach might be the creation of national database used as
reference for cost assessment.
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OBJECTIVES: During the last decade, with the arrival of new innovative vaccines,
there was a huge increase in the number of papers on economic evaluation of
vaccination programmes. Our study had a 3-fold objective: 1) Appraise available
methodological papers dealing with specificities of vaccines in term of health eco-
nomics; 2) Illustrate the impact of each issue in term of decision-making process
with concrete examples; and 3) Identify futures challenges. METHODS: A compre-
hensive literature search was conducted to identify methodological papers dealing
with specificities of economic evaluations of vaccines. Each issue was illustrated
with concrete examples of cost-effectiveness analyses recently performed for HPV
vaccines, or pneumococcal diseases. RESULTS: Except guidelines issued in 2008 by
the WHO and a few general papers, most of methodological papers focused on
modelling techniques and showed a trend in using more and more sophisticated
methods (e.g. calibration). Several papers highlighted the need for having strong
dynamic transmission models of infectious diseases to evaluate appropriately the
cost-effectiveness of vaccination programmes. Other papers focused on the issue
of discounting, and showed the extreme impact of discounting for some vaccines
given this long-term assessment, possibly warranting an alternative method of
discounting for vaccines. Fewer papers highlighted the different type of clinical
evidence compared with curative pharmaceutical drugs, in particular the need to
model immunological responses into clinical endpoints of disease and short-term
efficacy into long-term effectiveness. Although there is an increasing level of ex-
pertise in the field, other important issues such as the choice of realistic assump-
tions (coverage rates or vaccine prices) and the inclusion of externalities (i.e.
changes in the epidemiology of the infection) are not well analysed.
CONCLUSIONS: It is important for decision makers to keep in mind the above
vaccine specificities when they assess the cost-effectiveness of new vaccination
programmes in order to provide relevant conclusions.
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Increase in accessibility and affordability of health care services have been consid-
ered as important policy objectives since the beginning 1980s in Iran. However,
current 60- 70% out-of-pocket payments creates a barrier to an equal access to
quality health services especially in terms of new medicines. This affects equity
issues and consequently the “health” in Iran. Currently, the quasi-government
health insurance organizations considered as main budget holders or purchasers
of medicines and health care services, do not consider comprehensive economic
evaluations (Cost-effectiveness plus Budget impact analyses) for their reimburse-
ment decisions. The present study is introducing a standard Budget Impact Anal-
yses (BIAs) model for the first time in Iran. The main purpose is providing the health
care budget decision makers with a practical tool improving resource allocation as
well as accelerating and facilitating the process of pharmaceutical reimbursement
decision making to address the problem of considerable out-of-pocket payments in
Iran. In the current study, A literature systematic review was conducted on the
international database pubmed to find: 1) Standard guidelines published for BIAs
and 2) Empirical studies doing Pharmaceutical BIAs, published in English language
since Jan 2000 to Dec 2011. Four international standard guidelines and 22 empirical
studies on BIAs were reviewed to provide a comprehensive standard model for
conducting BIAs. They also include practical examples for theoretical recommen-
dations. Moreover, semi-structured interviews were also conducted to ask policy
makers opinions about the necessity of doing BIAs in Iran‘s health care financing
system as well as their opinions about the different parts of the proposed model.
The final model consists of general and detailed recommendations which were
extracted mainly from ISPOR task force report on Principles of Good Practice for
BIAs and other reviewed guidelines. There also were recommendations made by
Iranian policy makers which make the model much more practical for conducting
standard BIAs in Iran.
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OBJECTIVES: Many individuals with long-term care needs rely on informal care to
support them in their daily living. Although public authorities tend to see informal
care as free, caring imposes significant costs on caregivers. However, measuring
and valuing informal care remains a challenge partly due to the absence of clear
guidelines on the topic and partly due to the lack of consensus among economists
on the best methods to use. This review describes the methods used to measure
and monetarily value informal care and discusses their advantages and
limitations. METHODS: Review of: 1) the methods available to measure time; 2)
methods available to value informal care time; and 3) application in published
economic evaluations. RESULTS: Only the diary and the recall methods have been
used in cost-effectiveness analysis, although direct observation and experience
sampling may provide more accurate estimates of time use. The traditional meth-
ods to value time are the opportunity cost, proxy good and contingent valuation
methods. Recently, the well-being method and applications of conjoint analysis to
informal care have been developed. The value of informal care varies widely de-
pending on the methods used. CONCLUSIONS: Informal care should not be viewed
as costless or free since the time inputs into informal care generate costs borne by
the caregiver and society as a whole. Failure to consider informal care may affect
reimbursement decisions and shift costs to patients and their families. The mon-
etary value of informal care can be estimated using existing methods. The clear
advantage of using monetary methods is that results can potentially be included in
cost side of any type of economic evaluations. However, different methods give
different answers both in terms of time-use data and value of informal care. Clear
guidelines are needed on the preferred methods to measure and value informal
care time.
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OBJECTIVES: To assess the validity of cost calculation from incomplete data col-
lection and point out its consequence on bias and on precision of study results.
METHODS:Over a one-year period resource use data from 234 elderly patients with
myocardial infarction were collected quarterly. Applying unit costs, costs for each
quarter were estimated. To examine different strategies of incomplete data collec-
tion, two different methods (inter-/extrapolation) with three different time frames
(omitting quarter two and/or three) were applied and compared with complete
data collection. Sample size was recalculated in response to the variation of cost
estimates due to incomplete data collection. RESULTS: Sum of cost estimation
from complete and incomplete data collection in the case of omitting information
of quarter two or three showed no significant difference. When the time sampling
included only 50% of the full information (omitting quarter two and three) costs
were significantly lower by 3.9% (extrapolation) and 4.6% (interpolation). Generally,
an increase in the standard deviation by 1% leads to an increase in sample size by
2% in the case of a single outcome. Thus, based on observed increased standard
deviation due to incomplete cost collection a larger sample size by about 3% would
be required. This would be efficient, since more time is saved due to incomplete
data collection than extra time is required for additional patients. CONCLUSIONS:
In economic evaluation, cost data can be collected efficiently by reducing fre-
quency of data collection. This can be achieved by data collection for shorter peri-
ods (incomplete data collection) or extending recall windows (complete data col-
lection). When applying the method of incomplete data collection, sample size
calculation has to be modified due to increased standard deviation. This approach
is suitable to enable economic evaluation with lower costs to both study partici-
pants and investigators.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) devel-
oped—in a consultation process with an international expert panel—the efficiency
frontier (EF) approach to satisfy the legal requirements for economic evaluation in
Germany’s statutory health insurance system. Here we evaluate established tools
for assessing and communicating uncertainty in terms of their applicability to the
EF approach and, where necessary, suggest adjustments to them.METHODS: Tools
to dasplay uncertainty were applied to the EF approach with a simulated data set.
The tools are (i) displays of overall uncertainty (scatter plots, confidence bands,
contour plots); (ii) displays of uncertainty around the reimbursable price (confi-
dence intervals, a modified cost effectiveness acceptability curve, the net health/
monetary benefit approach), and (iii) the ANCOVA approach. RESULTS: We found
that, within the EF approach, the substantial implications of most tools was not
always easy to interpret. Hence, we propose the use of price reimbursement ac-
ceptability curves or the net health benefit approach. CONCLUSIONS: This closes a
gap for handling uncertainty in the economic evaluation approach of the IQWiG
methods. However, the role of statistical testing in determining reimbursable
prices is yet to be defined.
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OBJECTIVES: Consideration of the value presented to the health service by a new
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